Penumbra (PEN) Preferred Stock Liabilities (2014)

Penumbra (PEN) posted quarterly Preferred Stock Liabilities of $111.5 million for Q4 2014.

Penumbra (PEN) Preferred Stock Liabilities (2014) Analysis & Trends

Penumbra (PEN) has reported Preferred Stock Liabilities for 1 consecutive years, with $111.5 million the latest figure, recorded in Q4 2014.

In Q4 2014, Preferred Stock Liabilities changed N/A year-over-year to $111.5 million; the TTM figure through Dec 2014 stood at $111.5 million (changed N/A YoY), while the FY2014 annual figure was $111.5 million, up 98.26% from the prior year.
Preferred Stock Liabilities held at $111.5 million in Q4 2014 per PEN's latest filing.
Across five years, Preferred Stock Liabilities topped out at $111.5 million in Q4 2014 and bottomed at $111.5 million in Q4 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Abbott Laboratories	200.51 Bn	194.91 Bn	7.27 Bn	-
2	Stryker	129.96 Bn	126.48 Bn	4.50 Bn	-
3	Medtronic	120.18 Bn	110.96 Bn	6.41 Bn	-
4	Boston Scientific	74.28 Bn	73.74 Bn	3.85 Bn	-
5	Edwards Lifesciences	52.75 Bn	48.50 Bn	1.35 Bn	-
6	Dexcom	34.67 Bn	32.73 Bn	830.00 Mn	-
7	GE HealthCare Technologies	34.23 Bn	32.12 Bn	2.18 Bn	-
8	Koninklijke Philips	26.46 Bn	23.14 Bn	4.55 Bn	-
9	Steris	23.30 Bn	22.82 Bn	684.20 Mn	-
10	Penumbra	12.82 Bn	12.16 Bn	264.94 Mn	-

Download Data

Date	Value
Dec 31, 2014	111.47 Mn